---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Budget impact model discussion"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Budget impact model discussion. Topics: Manufacturer comments relevant to the budget impact inputs. 2 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics/budget-impact-model-discussion"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Budget impact model discussion

<a id="heading-4.2.7"></a>

## 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

### Summary

No budget impact model of lorundrostat from Mineralys or a health plan was identified; the only budget impact analysis is ICER's potential budget impact analysis in its 2026 evidence report, which uses a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost ($900 for 30 tablets). The analysis takes the cost-effectiveness model's health care costs, undiscounted, over five years, against an even split of spironolactone, eplerenone, and amiloride, whose median generic acquisition costs in ICER's model were $43 to $1,022 per year. It sized 10,042,828 United States adults with resistant hypertension on three or more drugs (Population 1) and 2,516,732 on two drugs who discontinued a third (Population 2, based on a 21% placeholder discontinuation estimate), 12,559,560 in total, and assumed 20% would initiate treatment in each year. At the placeholder price, the cumulative budget impact per patient treated was about $8,500 in year one and $16,300 by year five, and about 2% of eligible patients could be treated before annual spending reached ICER's threshold of $821 million; at the threshold prices, 100% could be treated against eplerenone and at the $50,000 per evLY prices against spironolactone ($630) and amiloride ($810). ICER did not size Population 3, patients on two drugs who have not tried a third, which overlaps the company's stated “third line or later” target. The analysis reports national figures and does not model a health plan membership; a 2026 poster hosted on the Mineralys website estimates, for a hypothetical 1 million–member plan, 194,140 treated adults with hypertension, 104,494 with uncontrolled hypertension, and 37,081 receiving three or more drugs. The actual budget impact will depend on a lorundrostat price not yet announced (Mineralys has referred to an SGLT2 inhibitor or Entresto price point at WAC and has given no rebate guidance), on rebates, and on displacement of baxdrostat, whose NADAC was $28.78424 per 2 mg tablet on 18 November 2026, and of generic mineralocorticoid receptor antagonists and amiloride, whose NADAC ranged from $0.04218 to $0.47438 per tablet.

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.7-2"></a>

### Manufacturer comments relevant to the budget impact inputs

> “Third, ICER should incorporate estimates of treatment discontinuation that are specific to the treatment and population being modelled.”
> “Given differences in patient behaviors across geographies and available evidence for the products being considered, as well as the sensitivity of results to the value of this input, we encourage ICER to ensure the best available data is being utilized to prevent biasing results.”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
